Trevogrumab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Trevogrumab
- human igg4 anti myostatin mab
- Human igg4 anti-myostatin mab
- HUMAN IGG4 TYPE MONOCLONAL ANTIBODY TO GDF8 (MYOSTATIN)
- human igg4 type monoclonal antibody to gdf8 myostatin
- HUMAN MONOCLONAL ANTIBODY TO GDF8 (MYOSTATIN)
- human monoclonal antibody to gdf8 myostatin
- regn 1033
- REGN-1033
- regn1033
- REGN1033
- REGN1033 (SAR391786)
- REGN1033(SAR391786)
- sar 391786
- SAR-391786
- sar391786
- SAR391786
- trevogrumab
- Trevogrumab
- trevogrumab [INN]
- TREVOGRUMAB [USAN]
- Trevogrumab [WHO-DD]
- trevogrumab inn
- trevogrumab usan
- trevogrumab who dd
- CAS registry numbers
- 1429201-24-0
- ChEMBL ID
- CHEMBL3545374
- FDA ingredient codes (UNII)
- 87T4327873
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- trevogrumab
- Type
- Antibody
- Drug name stem
- -mab
- Action
- Binding
- Action type
- Binding
- Target
- myostatin
- Gene symbol
- myostatin
- Median affinity
- 10.62
- Affinity units
- pKd
- Primary target
- Yes
- Mechanism
- Growth/differentiation factor 8 inhibitor
- Action type
- Inhibitor
- Target
- Growth/differentiation factor 8
- Protein identifier
- O14793
Open Targets mechanisms
- Mechanism
- Growth/differentiation factor 8 inhibitor
- Action type
- Inhibitor
- Target
- Growth/differentiation factor 8
- Condition
- Myositis, Inclusion Body
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007323
- Subject identifier
- D018979
- Condition
- Sarcopenia
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000653
- Subject identifier
- D055948
- Condition identifier
- EFO_0007323
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009851
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000653
- Highest recorded phase
- 2
- Condition identifier
- HP_0001513
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007827
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 2
- NCT01963598
- NCT03710941
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQVLESGGDLVQPGGSLRLSCAASGFTFSAYAMTWVRQAPGKGLEWVSAISGSGGSAYYADSVKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCAKDGAWKMSGLDVWGQGTTVIVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPASLSASVGDRVTITCRASQDISDYLAWYQQKPGKIPRLLIYTTSTLQSGVPSRFRGSGSGTDFTLTISSLQPEDVATYYCQKYDSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Related records
Trials (8)
- A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)
- A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
- Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
- Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men
- Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects
- Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
- Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)
- Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)
In development for (1)
- Inclusion body myositis Phase 2
Targets (1)
- MSTN Growth/differentiation factor 8 inhibitor